Nykredit A S Buys New Shares in Waters Corporation $WAT

Nykredit A S purchased a new position in Waters Corporation (NYSE:WAT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 38,061 shares of the medical instruments supplier’s stock, valued at approximately $14,274,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Anchor Investment Management LLC purchased a new position in shares of Waters during the 1st quarter worth about $27,000. Resources Management Corp CT ADV purchased a new stake in Waters in the first quarter valued at approximately $27,000. Zions Bancorporation National Association UT increased its position in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 40 shares during the last quarter. PenderFund Capital Management Ltd. purchased a new position in Waters during the second quarter worth approximately $28,000. Finally, Vision Retirement LLC purchased a new position in shares of Waters in the 1st quarter worth $29,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

WAT has been the subject of a number of research reports. Sanford C. Bernstein initiated coverage on Waters in a report on Friday, June 26th. They set an “outperform” rating and a $435.00 target price for the company. Stifel Nicolaus set a $420.00 price target on shares of Waters in a research report on Wednesday, August 5th. Royal Bank Of Canada boosted their price objective on shares of Waters from $435.00 to $475.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Bank of America raised their target price on shares of Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday, June 2nd. Finally, Guggenheim reaffirmed a “buy” rating and set a $440.00 price target on shares of Waters in a research report on Wednesday, July 8th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $424.35.

Waters News Roundup

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Shares are up 3.1% since the company’s most recent earnings report, reflecting investor confidence after Waters exceeded quarterly expectations with adjusted EPS of $3.05 versus the $3.01 consensus and revenue of $1.65 billion versus $1.62 billion expected. Why Is Waters Up Since Last Earnings Report?
• Positive Sentiment: Analysts currently assign Waters a consensus recommendation of “Moderate Buy,” providing continued support for the stock. The company also maintained 2026 earnings guidance of $14.45 to $14.65 per share. Waters Given Moderate Buy Recommendation
• Neutral Sentiment: Waters’ latest results included strong reported year-over-year revenue growth and an earnings beat, but investors may focus on whether that momentum is sustainable and whether the company can deliver its full-year outlook.
• Negative Sentiment: The stock trades at a very elevated valuation—approximately 102 times earnings—so expectations are high. Any weaker-than-expected demand, guidance revision, or margin pressure could produce volatility despite the positive analyst consensus.

Waters Price Performance

WAT opened at $409.39 on Friday. Waters Corporation has a twelve month low of $282.77 and a twelve month high of $426.22. The firm has a market cap of $40.22 billion, a price-to-earnings ratio of 102.09, a PEG ratio of 2.41 and a beta of 1.19. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. The company has a fifty day simple moving average of $391.93 and a 200 day simple moving average of $351.45.

Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, topping analysts’ consensus estimates of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same quarter in the previous year, the business posted $2.95 EPS. The firm’s revenue was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities research analysts expect that Waters Corporation will post 14.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Waters news, Director Christopher Kuebler sold 3,626 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the sale, the director owned 17,808 shares in the company, valued at $7,086,515.52. This trade represents a 16.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.